Billerica, Mass. — Bruker Corporation reported a 5.2 percent increase in second-quarter revenue, while a $134.9 million goodwill impairment charge pushed the scientific instruments company to a GAAP operating loss.
Revenue for the quarter ended June 30 rose to $838.5 million from $797.4 million in the same period last year. Organic revenue increased 2.8 percent, or 3.4 percent excluding tariff refunds.
Bruker Scientific Instruments revenue increased 4.7 percent to $767.3 million, with organic growth of 2.3 percent.
Revenue in the Bruker Energy & Supercon Technologies segment rose 11.9 percent to $74.2 million. Organic revenue in the segment increased 8.9 percent.
“We returned to organic revenue growth in the second quarter, and our Scientific Instruments segment achieved 10% organic bookings growth year over year,” said Frank H. Laukien, President and Chief Executive Officer of Bruker.
“Our focus on cost and profitability resulted in solid margin expansion and non-GAAP EPS growth in the quarter,” Laukien said.
The company reported a GAAP operating loss of $65.3 million, compared with operating income of $11.9 million a year earlier. The latest quarter included $134.9 million in noncash goodwill impairment charges.
Bruker reported a GAAP diluted loss of 41 cents per share, compared with earnings of 5 cents per share in the prior-year quarter.
On a non-GAAP basis, operating income increased to $118.5 million from $72 million. The non-GAAP operating margin expanded to 14.1 percent from 9 percent.
Non-GAAP diluted earnings increased to 49 cents per share from 32 cents per share.
Bruker said bookings in its Scientific Instruments segment increased 10 percent organically from a year earlier, with a book-to-bill ratio above 1.
The company reported strong order growth in semiconductor tools, energy research and biopharmaceutical markets. Demand from U.S. academic customers remained weak, while academic and government bookings in Europe and China increased.
“We are gaining confidence in a gradual market recovery, and we anticipate significant organic margin expansion and non-GAAP EPS growth not only this year, but in 2027 as well,” Laukien said.
For the first six months of 2026, revenue increased 3.9 percent to $1.7 billion from $1.6 billion. Organic revenue declined 0.8 percent.
Bruker Scientific Instruments revenue increased 3.3 percent to $1.5 billion, although organic revenue fell 1.4 percent.
First-half revenue in the Bruker Energy & Supercon Technologies segment increased 12.3 percent to $141 million, with organic growth of 6.1 percent.
The company reported a first-half GAAP operating loss of $55.1 million, compared with operating income of $43.7 million in the same period last year.
Non-GAAP operating income increased to $202.7 million from $173.7 million, while the non-GAAP operating margin rose to 12.2 percent from 10.9 percent.
Bruker reported a first-half GAAP diluted loss of 39 cents per share, compared with earnings of 16 cents per share a year earlier. Non-GAAP diluted earnings increased to 80 cents per share from 78 cents.
Bruker updated its full-year 2026 outlook to reflect changes in foreign exchange rates and taxes.
The company expects revenue of $3.54 billion to $3.57 billion, representing reported growth of 3 percent to 4 percent from 2025.
The forecast includes organic revenue growth of 1 percent to 2 percent, acquisition-related growth of about 1.5 percent and a foreign currency translation benefit of about 0.5 percent.
Bruker maintained its forecast for non-GAAP earnings of $2.10 to $2.15 per share, representing growth of 15 percent to 17 percent from $1.83 per share in 2025.
The earnings outlook includes an estimated currency-related headwind of about 10 cents per share.
